Sorafenib treatement for recurrent stage T1 bilateral renal cell carcinoma in patients with Von Hippel- Lindau disease: A case report and literature review

Authors

  • Kyung Hwa Choi Department of Urology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
  • Young Dong Yu Department of Urology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
  • Moon Hyung Kang Department of Urology, CHA Bundang Medical Center, CHA University, Seongnam, Korea
  • Dong Soo Park Department of Urology, CHA Bundang Medical Center, CHA University, Seongnam, Korea

DOI:

https://doi.org/10.5489/cuaj.2863

Keywords:

Von Hippel- Lindau disease, Renal cell carcinoma, Sorafenib

Abstract

Renal cell carcinoma (RCC) with Von Hippel-Lindau (VHL) syndrome is associated with multiple recurrences and a young age at diagnosis. Therefore the primary goal of treatment is to stabilize the disease, minimizing the surgical resection and preserving the renal function in the patients with VHL who have developing RCC nodules after initial treatment. This is the first case report of VHL disease, with long-term stable disease, treated with a half dose of sorafenib after surgical resection and radiofrequency ablation for multiple recurrent stage T1 masses. We discuss the efficacy and safety of low-dose sorafenib treatment and review RCC in a patient with VHL disease.

Downloads

Download data is not yet available.

Downloads

Published

2015-09-09

How to Cite

Choi, K. H., Yu, Y. D., Kang, M. H., & Park, D. S. (2015). Sorafenib treatement for recurrent stage T1 bilateral renal cell carcinoma in patients with Von Hippel- Lindau disease: A case report and literature review. Canadian Urological Association Journal, 9(9-10), E651–3. https://doi.org/10.5489/cuaj.2863

Issue

Vol. 9 No. 9-10 (2015): CUAJ September

Section

Case Report

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.